BioSpace News Archive

Today, LGC announced the acquisition of Technopath Clinical Diagnostics, a global leader in the development and manufacture of quality control (QC) solutions for clinical laboratories.

Adamas Pharmaceuticals, Inc. (Nasdaq: ADMS), a company dedicated to developing and delivering medicines that make a meaningful difference to people affected by neurological diseases, today announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for a supplemental New Drug Application for GOCOVRI® (amantadine)

Inflammasome Therapeutics (https://www.inflam.com), a privately held company developing therapies for prevalent, degenerative diseases, today reported that data analyses published in the current issue of Proceedings of the National Academy of Sciences (PNAS) confirms that the Company’s proprietary compounds hold significant promise in the prevention and treatment of age-related macular degeneration (dry AMD), a leading cause of vision loss in people more than 60 years of age.

Breg, Inc., a leading orthopedic bracing and billing services company, has announced the launch of two new lines of spinal orthoses: Pinnacle and Ascend™.

Vancouver, British Columbia--(Newsfile Corp. - February 1, 2021) - BioVaxys Technology Corp. (CSE: BIOV) (“BioVaxys” or the “Company”), is pleased to announce a non-brokered private placement (the “Private Placement”) consisting of 4,313,725 units (“Units”) at a price of $0.255 per Unit for total gross proceeds of approximately $1,100,000.

Company invites individual and institutional investors, as well as advisors and analysts, to attend real-time, interactive presentations on VirtualInvestorConferences.com

The newest addition to the Beltone hearing aid portfolio, Beltone Rely delivers proven hearing technology, leading rechargeability, connectivity and at-home hearing care support.

Labcorp, a leading global life sciences company, announced that it has been named to FORTUNE® magazine’s 2021 List of World’s Most Admired Companies, making the annual list for the third time.

Livanta LLC (“Livanta”) announced that it has attained compliance with the International Organization for Standardization (ISO) 9001:2015 requirements for the third consecutive year, earning re-certification through December 2023

Revolution Medicines, Inc. announced that it has commenced an underwritten public offering of 4,000,000 shares of common stock.